Viewray Inc., the manufacturer of the Mridian MR-guided radiation therapy system, released disappointing preliminary first quarter 2023 results and shareholders braced for more bad news as the company reported it engaged Goldman Sachs to evaluate strategic alternatives including corporate sale, merger or business combination.